Utrecht

• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24 Atopic Dermatitis
• A clinical study of MK-0616 for people with high amounts of low-density lipoprotein cholesterol Ended
  2022-502782-14-00 5 2023-09-28 Heterozygous Familial Hypercholesterolemia (HeFH)
• Long-term extension study of ligelizumab in food allergy Ended
  2022-502366-25-00 5 2023-09-11 Food allergy
• PREPARE-iVAC Ended
  2023-503894-39-00 11 2023-08-22 kidney transplantation
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease
• Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended
  2024-516321-31-00 4 2023-07-07 Type 3 spinal muscular atrophy
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype … Ended
  2022-503022-13-00 5 2023-06-08 Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
• A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have heart disease due to TTR amy … Ended
  2023-506824-96-00 4 2023-05-23 The present study will include a population of patients with establish
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• A Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients wit … Ended
  2022-501793-19-00 5 2023-04-21 Uveitic Macular Edema
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended
  2023-504540-33-00 5 2023-03-06 COVID-19
• Safety and Tolerability of AC01 in patients with heart failure Ended
  2022-500347-20-00 9 2023-02-23 Heart Failure
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A clinical study to evaluate mRNA-3705 in Patients with MMA Ended
  2022-502492-32-00 7 2023-02-03 Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Defici
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis. Ended
  2024-512791-36-00 4 2022-08-24 Treatment of moderate-to-severe Atopic dermatitis
• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction

Showing 553–576 of 628 trials